Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Experts are expecting strong results driven by Trulicity manufacturer the strong demand of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential cha